1. Michelson Diagnostics

    0 Comments Leave a Comment

    1-15 of 190 1 2 3 4 ... 11 12 13 »
    1. Mentioned In 190 Articles

    2. Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT

      Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT
      ...lished in a leading peer review journal later this year. About Michelson Diagnostics and the VivoSight System Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam...
      Read Full Article
    3. Positive results from multi-centre, prospective clinical trial for diagnosis of basal cell carcinoma using Michelson Diagnostics’ VivoSight OCT Presented at AAD

      Positive results from multi-centre, prospective clinical trial for diagnosis of basal cell carcinoma using Michelson Diagnostics’ VivoSight OCT Presented at AAD
      ...t the skin, and in particular non-melanoma skin cancer. For further information come and meet the team at the Michelson Diagnostics booth, number 2255 - http://show.aad.org/annual14/EC/forms/attendee/indexTab.aspx

      Read Full Article
    4. Motion tracking to enable pre-surgical margin mapping in basal cell carcinoma using optical imaging modalities: initial feasibility study using optical coherence tomography

      Motion tracking to enable pre-surgical margin mapping in basal cell carcinoma using optical imaging modalities: initial feasibility study using optical coherence tomography

      A system has been developed to assess the feasibility of using motion tracking to enable pre-surgical margin mapping of basal cell carcinoma (BCC) in the clinic using optical coherence tomography (OCT). This system consists of a commercial OCT imaging system (the VivoSight 1500, MDL Ltd., Orpington, UK), which has been adapted to incorporate a webcam and a single-sensor electromagnetic positional tracking module (the Flock of Birds, Ascension Technology Corp, Vermont, USA). A supporting software interface has also been developed which allows positional data to be captured and projected onto a 2D dermoscopic image in real-time. Initial results using a stationary ...

      Read Full Article
    5. Axsun Technologies Announces Volume Purchase Order for Swept Laser Engines from Michelson Diagnostics Ltd.

      Axsun Technologies Announces Volume Purchase Order for Swept Laser Engines from Michelson Diagnostics Ltd.
      ...r Swept Laser OCT Engines from Michelson Diagnostics Ltd. The Axsun Swept Laser OCT Engine will power the new Michelson Diagnostics' Vivosight Multi-Beam OCT system. The Vivosight Multi-Beam OCT system is the first OCT s...
      Read Full Article
    6. Global optical imaging market is anticipated to be approximately around $1.9 billion by end of 2018, growing at a CAGR of 11.37%.

      Global optical imaging market is anticipated to be approximately around $1.9 billion by end of 2018, growing at a CAGR of 11.37%.
      ...oo, will likely improve as the technology becomes more available. The key players profiled in the report are Michelson Diagnostics, Heidelberg Engineering GmBH, Carl Zeiss Meditec, Volcano Corporation, Topcon Medical Sy...
      Read Full Article
    7. Optical coherence tomography: What is optical coherence tomography?

      Optical coherence tomography:  What is optical coherence tomography?

      Optical coherence tomography (OCT) is a non-invasive optical imaging technique that uses low-power infrared laser light to image up to 2 mm beneath the skin surface. The clinician can obtain real-time images of the architecture of the skin without pretreatment or gels. OCT has been shown to be a useful diagnostic tool in diagnosing early stage skin cancer [1]. What lies beneath the skin surface can be seen in vivo, without the need for skin biopsy [2]. Studies have compared OCT findings with histopathology, establishing the OCT characteristics of actinic keratoses , in-situ squamous cell carcinoma (SCC), and basal cell carcinoma ...

      Read Full Article
    8. Optical Coherence Tomography for presurgical margin assessment of non‐melanoma skin cancer‐a practical approach

      Optical Coherence Tomography for presurgical margin assessment of non‐melanoma skin cancer‐a practical approach
      ..., Skin Cancer Centre Charité, Department of Dermatology, Venereology and Allergology, Berlin, Germany 2. ^2 Michelson Diagnostics Ltd, Kent, UK ^* Corresponding author: Seyed Arash Alawi Charité – Universitätsmedizin B...
      Read Full Article
    9. 1-15 of 190 1 2 3 4 ... 11 12 13 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources, Velocimetry
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Michelson Diagnostics

    Michelson Diagnostics

    Michelson Diagnostics.  Microscopy Systems.  Michelson Diagnostics Ltd (MDL) is a healthcare company providing a live view of cancerous tissue.  The company was formed in March 2006 to develop a hand-held cancer scanner based on an imaging technology called optical coherence tomography (OCT).   The patented device will give clinicians and researchers a live view of sub-surface tissue structures at near-cellular resolution - high enough to see the emergence and growth of cancer. It shows tissue as deep as 2 mm and offers much higher image resolution than ultrasound or MRI.  The non-invasive cancer scan reduces the need for painful and costly biopsies and provides patients and doctors with immediate results. Whole organs can be systematically scanned for abnormalities.

  3. Quotes about Michelson Diagnostics

    1. I found the MedTech Tour Summit extremely useful: the high standard of presenting companies at different stages of their business development provided insights into how I need to position Michelson Diagnostics for an investment. I also made contact with several interested investors and advisors, and discussions are progressing.
      Jon Holmes in Michelson Diagnostics is Singled Out for Growth
    2. Michelson Diagnostics has applied their outstanding technology to forward thinking products and I am extremely pleased to be representing the company in the US.
      Kevin C. Oakley in Michelson Diagnostics Opens US Offices And Appoints US Business Development Manager
    3. This is a remarkable milestone for Michelson Diagnostics, as it shows, through a statistically significant sample, that multi-beam OCT technology has the potential to play an important role in the early diagnosis of cancer.
      Jon Holmes in Michelson Diagnostics Reports First Quantitative Results on Cancer Diagnosis Using Multi-beam OCT imaging